AbClon

[Not Yet Scheduled]
AbClon is a public biotech company based in Seoul, South Korea and it is listed in KOSDAQ (Korean Stock Exchange) since September 2017. It has proprietary technology platforms for development of therapeutic antibodies: NEST, AffiMab and switchable CAR-T. Using these unique tech platforms, AbClon is developing novel therapeutic antibodies to improve patients’ benefit. The co-founders of AbClon are the scientists directing Human Protein Atlas project in Sweden, and an
antibody research team based in Seoul, Korea. AbClon is collaborating with multiple partners including Swedish Collaborators, Seoul National University, Yuhan Inc. and Shanghai Henlius Biotech for novel antibody-based therapeutics. AbClon has also customer service program, ADDs (Antibody Drug Development support), to provide tailored antibodies for research or commercial collaborations.
Ticker:
174900
Exchange:
KRX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
AC101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CSO
AbClon